Pyrimidine deoxynucleoside and nucleoside reverse transcriptase inhibitor metabolism in the perfused heart and isolated mitochondria

Gerald W. Morris, Darcy D. LaClair, Edward E. McKee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The metabolism of pyrimidine deoxynucleosides and nucleoside reverse transcriptase inhibitors has been studied in growing cells. However, many of these drugs are associated with mitochondrial toxicities observed in nonreplicating tissues, such as in the heart, where their metabolism has not been investigated. Methods: The aims of this study were twofold. The first was to investigate the metabolism of the thymidine analogues 3′-azido-3′ deoxythymidine (AZT) and 2′,3′-didehydrodideoxy-thymidine (d4T), and the deoxycytidine (dCyd) analogues 2′-deoxy-3′ thiacytidine (3TC) and 2′,3′-dideoxycytidine (ddC) with regard to phosphorylation and breakdown. The second was to investigate their potential effects, singly or in combination with AZT, on metabolism of the naturally occurring deoxynucleosides in the perfused rat heart and in isolated heart mitochondria. Results: The analogue d4T was not metabolized in perfused heart or in isolated mitochondria, and had no effect on either thymidine or dCyd metabolism. The dCyd analogues were both phosphorylated in perfused heart to the triphosphate, but only at the limit of detection and they were not phosphorylated in isolated mitochondria. Neither ddC nor 3TC had any effect on thymidine or dCyd metabolism in either perfused heart or in isolated mitochondria. AZT has been previously shown to inhibit thymidine phosphorylation. When d4T, 3TC or ddC were given with AZT, only ddC caused a significant further decrease in thymidine phosphorylation. Conclusions: These results indicate that with the exception of the competition between AZT and thymidine, there was little competition for phosphorylation among and between these other nucleoside reverse transcriptase inhibitors and the naturally occurring deoxynucleosides in cardiac tissue and isolated heart mitochondria.

Original languageEnglish (US)
Pages (from-to)587-597
Number of pages11
JournalAntiviral Therapy
Volume15
Issue number4
DOIs
StatePublished - Sep 24 2010

Fingerprint

Pyrimidine Nucleosides
Heart Mitochondria
Reverse Transcriptase Inhibitors
Thymidine
Zalcitabine
Deoxycytidine
Phosphorylation
Mitochondria
Zidovudine
Nucleosides
Limit of Detection

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Pyrimidine deoxynucleoside and nucleoside reverse transcriptase inhibitor metabolism in the perfused heart and isolated mitochondria. / Morris, Gerald W.; LaClair, Darcy D.; McKee, Edward E.

In: Antiviral Therapy, Vol. 15, No. 4, 24.09.2010, p. 587-597.

Research output: Contribution to journalArticle

Morris, Gerald W. ; LaClair, Darcy D. ; McKee, Edward E. / Pyrimidine deoxynucleoside and nucleoside reverse transcriptase inhibitor metabolism in the perfused heart and isolated mitochondria. In: Antiviral Therapy. 2010 ; Vol. 15, No. 4. pp. 587-597.
@article{dfe688b0e6ed492a879fd08b4fc3f881,
title = "Pyrimidine deoxynucleoside and nucleoside reverse transcriptase inhibitor metabolism in the perfused heart and isolated mitochondria",
abstract = "Background: The metabolism of pyrimidine deoxynucleosides and nucleoside reverse transcriptase inhibitors has been studied in growing cells. However, many of these drugs are associated with mitochondrial toxicities observed in nonreplicating tissues, such as in the heart, where their metabolism has not been investigated. Methods: The aims of this study were twofold. The first was to investigate the metabolism of the thymidine analogues 3′-azido-3′ deoxythymidine (AZT) and 2′,3′-didehydrodideoxy-thymidine (d4T), and the deoxycytidine (dCyd) analogues 2′-deoxy-3′ thiacytidine (3TC) and 2′,3′-dideoxycytidine (ddC) with regard to phosphorylation and breakdown. The second was to investigate their potential effects, singly or in combination with AZT, on metabolism of the naturally occurring deoxynucleosides in the perfused rat heart and in isolated heart mitochondria. Results: The analogue d4T was not metabolized in perfused heart or in isolated mitochondria, and had no effect on either thymidine or dCyd metabolism. The dCyd analogues were both phosphorylated in perfused heart to the triphosphate, but only at the limit of detection and they were not phosphorylated in isolated mitochondria. Neither ddC nor 3TC had any effect on thymidine or dCyd metabolism in either perfused heart or in isolated mitochondria. AZT has been previously shown to inhibit thymidine phosphorylation. When d4T, 3TC or ddC were given with AZT, only ddC caused a significant further decrease in thymidine phosphorylation. Conclusions: These results indicate that with the exception of the competition between AZT and thymidine, there was little competition for phosphorylation among and between these other nucleoside reverse transcriptase inhibitors and the naturally occurring deoxynucleosides in cardiac tissue and isolated heart mitochondria.",
author = "Morris, {Gerald W.} and LaClair, {Darcy D.} and McKee, {Edward E.}",
year = "2010",
month = "9",
day = "24",
doi = "10.3851/IMP1567",
language = "English (US)",
volume = "15",
pages = "587--597",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "4",

}

TY - JOUR

T1 - Pyrimidine deoxynucleoside and nucleoside reverse transcriptase inhibitor metabolism in the perfused heart and isolated mitochondria

AU - Morris, Gerald W.

AU - LaClair, Darcy D.

AU - McKee, Edward E.

PY - 2010/9/24

Y1 - 2010/9/24

N2 - Background: The metabolism of pyrimidine deoxynucleosides and nucleoside reverse transcriptase inhibitors has been studied in growing cells. However, many of these drugs are associated with mitochondrial toxicities observed in nonreplicating tissues, such as in the heart, where their metabolism has not been investigated. Methods: The aims of this study were twofold. The first was to investigate the metabolism of the thymidine analogues 3′-azido-3′ deoxythymidine (AZT) and 2′,3′-didehydrodideoxy-thymidine (d4T), and the deoxycytidine (dCyd) analogues 2′-deoxy-3′ thiacytidine (3TC) and 2′,3′-dideoxycytidine (ddC) with regard to phosphorylation and breakdown. The second was to investigate their potential effects, singly or in combination with AZT, on metabolism of the naturally occurring deoxynucleosides in the perfused rat heart and in isolated heart mitochondria. Results: The analogue d4T was not metabolized in perfused heart or in isolated mitochondria, and had no effect on either thymidine or dCyd metabolism. The dCyd analogues were both phosphorylated in perfused heart to the triphosphate, but only at the limit of detection and they were not phosphorylated in isolated mitochondria. Neither ddC nor 3TC had any effect on thymidine or dCyd metabolism in either perfused heart or in isolated mitochondria. AZT has been previously shown to inhibit thymidine phosphorylation. When d4T, 3TC or ddC were given with AZT, only ddC caused a significant further decrease in thymidine phosphorylation. Conclusions: These results indicate that with the exception of the competition between AZT and thymidine, there was little competition for phosphorylation among and between these other nucleoside reverse transcriptase inhibitors and the naturally occurring deoxynucleosides in cardiac tissue and isolated heart mitochondria.

AB - Background: The metabolism of pyrimidine deoxynucleosides and nucleoside reverse transcriptase inhibitors has been studied in growing cells. However, many of these drugs are associated with mitochondrial toxicities observed in nonreplicating tissues, such as in the heart, where their metabolism has not been investigated. Methods: The aims of this study were twofold. The first was to investigate the metabolism of the thymidine analogues 3′-azido-3′ deoxythymidine (AZT) and 2′,3′-didehydrodideoxy-thymidine (d4T), and the deoxycytidine (dCyd) analogues 2′-deoxy-3′ thiacytidine (3TC) and 2′,3′-dideoxycytidine (ddC) with regard to phosphorylation and breakdown. The second was to investigate their potential effects, singly or in combination with AZT, on metabolism of the naturally occurring deoxynucleosides in the perfused rat heart and in isolated heart mitochondria. Results: The analogue d4T was not metabolized in perfused heart or in isolated mitochondria, and had no effect on either thymidine or dCyd metabolism. The dCyd analogues were both phosphorylated in perfused heart to the triphosphate, but only at the limit of detection and they were not phosphorylated in isolated mitochondria. Neither ddC nor 3TC had any effect on thymidine or dCyd metabolism in either perfused heart or in isolated mitochondria. AZT has been previously shown to inhibit thymidine phosphorylation. When d4T, 3TC or ddC were given with AZT, only ddC caused a significant further decrease in thymidine phosphorylation. Conclusions: These results indicate that with the exception of the competition between AZT and thymidine, there was little competition for phosphorylation among and between these other nucleoside reverse transcriptase inhibitors and the naturally occurring deoxynucleosides in cardiac tissue and isolated heart mitochondria.

UR - http://www.scopus.com/inward/record.url?scp=77956798224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956798224&partnerID=8YFLogxK

U2 - 10.3851/IMP1567

DO - 10.3851/IMP1567

M3 - Article

C2 - 20587852

AN - SCOPUS:77956798224

VL - 15

SP - 587

EP - 597

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 4

ER -